MediciNova Announces Phase 3 Clinical Trial Plan for MN-166 (ibudilast) in Progressive MS
MediciNova, Inc. (MNOV)
Last medicinova, inc. earnings: 4/23 04:20 pm
Check Earnings Report
US:NASDAQ Investor Relations:
medicinova.com/investor-relations/media-archive
Company Research
Source: GlobeNewswire
LA JOLLA, Calif., July 11, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced its plans for a Phase 3 clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS) following feedback from the FDA (U.S. Food and Drug Administration). Key elements of MediciNova’s Phase 3 clinical trial plan for MN-166 (ibudilast) in progressive MS include the following: • MediciNova’s Phase 3 trial will enroll only subjects with secondary progressive MS without relapses. The rationale for enrolling this type of progressive MS is the following: The FDA agreed that a population of subjects with secondary progressive MS without relapses is an appropriate target population.MediciNova believes that subjects with secondary progressive MS without relapses will have the best clinical response to MN-166 (ibudilast) treatment, a
Show less
Read more
Impact Snapshot
Event Time:
MNOV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNOV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNOV alerts
High impacting MediciNova, Inc. news events
Weekly update
A roundup of the hottest topics
MNOV
News
- MediciNova, Inc. (NASDAQ: MNOV) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- MediciNova, Inc. (NASDAQ: MNOV) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- MediciNova, Inc. (NASDAQ: MNOV) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)GlobeNewswire
- MediciNova, Inc. (NASDAQ: MNOV) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
MNOV
Earnings
- 11/9/23 - Beat
MNOV
Sec Filings
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form ARS
- 4/26/24 - Form DEF
- MNOV's page on the SEC website